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The Focus article "Double Exposure"
[EHP 107:A196-A201 (1999)] mistakenly
reported that a meta-analysis ofepidemiol-
ogy studies examining the relationship
between exposure to environmental tobac-
co smoke (ETS) and human cancer was
prepared for the review of ETS in consid-
eration for listing in the National
Toxicology Program (NTP) Report on
Carcinogens. We would like to point out
that the results of several published meta-
analyses were considered during the ETS
review, but that the NTP did not, in fact,
perform an additional meta-analysis of
these data.
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Paraoxonase/MCS
Work in multiple laboratories on paraox-
onase polymorphism has shown that this
mammal enzyme protects against chlor-
pyrifos and other organophosphates differ-
entially, depending on which inherited
forms of the enzyme predominate. This
variable ability to process pesticides exists
in humans and is trackable ethnically (1),
and very recent articles have suggested the
polymorphism may be responsible for host
susceptibility to GulfWar syndrome (2,3).
Because my own interest is in multiple
chemical sensitivity (MCS) mechanisms, I
immediately searched Medline (National
Library of Medicine, Bethesda, MD) for
publications that included paraoxonase
and MCS, fibromyalgia, or chronic fatigue
syndrome (CFS), which have been suggest-
ed as being overlapping or identical with
each other and with Gulf War syndrome
(4,5). I found no other references at all.
I believe that there is a significant pos-
sibility that paraoxonase is important in
these conditions. A meta-model generating
six examples of MCS mechanisms that
could arise during situations of chemical
damage or rapid contextual change has
previously been shown (6). The first of
these models, and apparently the most
likely on the basis of existing clinical evi-
dence, is pesticide damage to the central
nervous system, in which exposures to
chlorpyrifos and other organophosphates
figure prominently in the supporting data.
In addition, another ofthe models explores
how host genetic variability in immune
response could lead, through conditioning,
to the heightened reactions to low levels of
other toxicants that is characteristic of
MCS, CFS, fibromyalgia (4), and Gulf
War syndrome (5). Both of these multiple
chemical sensitivity models could be satis-
fied simultaneously by the genetic varia-
tion of an enzyme that controls the ability
to resist damage from pesticides-an
enzyme such as paraoxonase.
This suggests that it may be worthwhile
to test statistically significant sizes ofMCS,
CFS, fibromyalgia, and GulfWar syndrome
patient populations to determine what
paraoxonase polymorphisms they carry. Ifit
were determined in any one ofthese popu-
lations that the condition is genetically
determined by reduced paraoxonase levels
or activity, this would solve the debate
about psychogenic or biogenic origins of
that condition. Additionally, it would allow
research funding to be confidently spent fol-
lowing up the mechanism, i.e., determining
exactly how the inability to process these
insecticides results in the condition.
A new study correlates significantly
lower frequency and activity of PON1-Q
paraoxonase polymorphism, which process-
es several organophosphates including some
nerve gases, with a symptomatic group of
GulfWar syndrome veterans, as compared
to well controls (7). This study has in effect
carried out my suggestion for one of the
groups, and its result strongly implies the
need to do the same for the others: MCS,
fibromyalgia, and CFS.
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